Study on early diagnosis and Prognostic markers of Hepatocellular carcinoma based on ctDNA methylation

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2100043640

Enrollment

Unknown

Registered

2021-02-24

Start date

2021-03-01

Completion date

Unknown

Last updated

2021-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular carcinoma

Interventions

Gold Standard:Pathologic diagnosis

Index test:ctDNA

Eligibility

Sex/Gender

All

Age

18 Years to 88 Years

Inclusion criteria

Inclusion criteria: 1.Age from 18 to 88 years; 2.Patients with hepatitis B and liver cirrhosis; 3.Patients with early and advanced hepatocellular carcinoma according to BCLC.

Exclusion criteria

Exclusion criteria: 1.Patients with incomplete information; 2.Patients with a history of hepatocellular carcinoma surgery, or other cancer history, or receiving any chemotherapy or radiotherapy; 3.Pregnant women.

Design outcomes

Primary

Measure	Time frame
DNA;SEN, SPE, ACC, AUC of ROC, PPV, NPV;	—

Secondary

Measure	Time frame
AFP;DCP;	—

Countries

China

Contacts

Public ContactWei Lu

Tianjin Medical University Cancer Institute and Hospital

mail4luwei@163.com+86 22-27468682

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026